Teva Granted ANDA Approval for Eisai's Aciphex
This article was originally published in PharmAsia News
Executive Summary
Although Teva's ANDA for rabeprazole delayed-release tablets (Eisai's Aciphex) has been approved, the company told "The Pink Sheet" DAILY Feb. 22 that it will not immediately launch the product
You may also be interested in...
Aciphex Patent Case Will Continue On Enforceability Grounds
Eisai wins a summary judgment against Dr. Reddy’s and Teva on the validity of its rabeprazole patent but must go to trial on enforceability claims.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).